Red Hair Genetics: 5 Things You May Not Know
…hair at risk for melanoma? The answer is a definite YES. Those with natural red hair, light eyes, and light…
Red Hair Genetics: 5 Things You May Not Know
…hair at risk for melanoma? The answer is a definite YES. Those with natural red hair, light eyes, and light…
Melanoma Does Not Define Rebecca Berger
…throughout my melanoma journey. Could you describe how sharing your story has affected your journey with melanoma? I have always…
,
Melanoma by the State: Montana
…Yet, despite its large geographic size and land diversity, Montana has only about one million residents, making it the 44th…
,
The Importance of Peer Support when Battling Melanoma
…found each other through the Peer Connect program, a free service provided by AIM at Melanoma Foundation. The program matches…
,
FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma
…International Melanoma Tissue Bank Consortium, The Melanoma International Collaboration for Adaptive Trials, and the International Melanoma Working Group. AIM at…
,
FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
…and, ultimately, the cure for melanoma while improving the lives of those it affects. AIM’s global research initiatives include The…
,
May is National Melanoma and Skin Cancer Awareness Month
Dear Friends, As most everyone in the melanoma community knows, May is National Melanoma and Skin Cancer Awareness Month. What…
,
How ctDNA is Shaping the Future of Melanoma Care
In this informative webinar, Melissa Wilson, PA-C, MPAS, Melanoma Lead at UPMC Hillman Cancer Center, and medical expert with AIM…
From Service to Survival: A Veteran’s Battle with Melanoma
…melanoma prevention and supporting other survivors, especially veterans. He has mentored a fellow veteran through Peer Connect, AIM at Melanoma’s…
,
Motherhood and Melanoma: Raleigh Minning, Stage III Melanoma Survivor
…she was that familiar with,” Raleigh said. It was the first of many times she realized how little is known…
,
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026